Related Experiment Video
Updated: May 16, 2026

In Vivo Imaging and Quantitation of the Host Angiogenic Response in Zebrafish Tumor Xenografts
Published on: August 14, 2019
Vasculitis in New Zealand.
1Department of Renal Medicine, North Shore Hospital, Waitemata District Health Board, 122 Shakespeare Road, Takapuna, Auckland, 0740, New Zealand. janak.dezoysa@waitematadhb.govt.nz.
Vasculitis, including giant cell arteritis and Kawasaki disease, is uncommon in New Zealand but significantly impacts patient health and survival. This review details its prevalence and incidence across different age groups.
Area of Science:
- Rheumatology
- Epidemiology
- Public Health
Background:
- Review prepared for the 2012 Asia Pacific Meeting for Vasculitis and ANCA Workshop.
- Focuses on vasculitis epidemiology in New Zealand.
Purpose of the Study:
- To review the incidence and prevalence of various vasculitis types in New Zealand.
- To highlight the public health impact of vasculitis in the NZ population.
Main Methods:
- Analysis of New Zealand demographic and health data.
- Inclusion of relevant studies on vasculitis originating from New Zealand.
Main Results:
- Giant cell arteritis incidence: 12.7/100,000 adults over 50 years.
- Kawasaki disease incidence: 8.0/100,000 children under 5 years.
- Granulomatosis with polyangiitis prevalence: 29-75 cases/million; dual anti-GBM/ANCA vasculitis incidence: 0.47/million.
Conclusions:
- Vasculitis represents an uncommon yet significant cause of illness and death in New Zealand.
- Understanding regional epidemiology is crucial for managing these rare diseases.
Related Concept Videos
Endocarditis II: Clinical Features of Infective Endocarditis
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Endocarditis I: Introduction
